期刊
SCHIZOPHRENIA RESEARCH
卷 164, 期 1-3, 页码 136-142出版社
ELSEVIER
DOI: 10.1016/j.schres.2015.01.041
关键词
Schizophrenia; Cognition; Histamine H-3 antagonist; CogState Schizophrenia Battery; MATRICS Consensus Cognition Battery; GSK239512
类别
资金
- GlaxoSmithKline
- NIH [1R21-MH101685-01A1, 1R21-MH101685-02, RC3-MH090833-01]
- Singapore National Medical Research Council [NMRC/TCR/003/2008]
- Research Foundation for Mental Hygiene [96074]
This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H-3 receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7 weeks (4 weeks titration). GSK239512 was associated with a small positive effect size (ES) on the CogState Schizophrenia Battery (CSSB) Composite Score (ES = 0.29, CI = -0.40, 0.99) relative to placebo (primary endpoint). GSK239512's ES on CSSB domains were generally positive or neutral except Processing Speed, which favored placebo (ES = -0.46). Effects on the MATRICS Consensus Cognitive Battery were mostly neutral or favored placebo. GSK239512 was generally well tolerated with an adverse event profile consistent with the known class pharmacology. There was no evidence of overall beneficial effects of GSK239512 for CIAS in this population. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据